Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients.
Publication
, Journal Article
Ni, B; Wolfe, CR; Arif, S; Carugati, M; Heldman, MR; Messina, JA; Miller, RA; Saullo, JL; Baker, AW; Maziarz, EK
Published in: Open Forum Infect Dis
July 2024
We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Open Forum Infect Dis
DOI
ISSN
2328-8957
Publication Date
July 2024
Volume
11
Issue
7
Start / End Page
ofae335
Location
United States
Related Subject Headings
- 3207 Medical microbiology
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Ni, B., Wolfe, C. R., Arif, S., Carugati, M., Heldman, M. R., Messina, J. A., … Maziarz, E. K. (2024). Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients. Open Forum Infect Dis, 11(7), ofae335. https://doi.org/10.1093/ofid/ofae335
Ni, Bin, Cameron R. Wolfe, Sana Arif, Manuela Carugati, Madeleine R. Heldman, Julia A. Messina, Rachel A. Miller, Jennifer L. Saullo, Arthur W. Baker, and Eileen K. Maziarz. “Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients.” Open Forum Infect Dis 11, no. 7 (July 2024): ofae335. https://doi.org/10.1093/ofid/ofae335.
Ni B, Wolfe CR, Arif S, Carugati M, Heldman MR, Messina JA, et al. Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients. Open Forum Infect Dis. 2024 Jul;11(7):ofae335.
Ni, Bin, et al. “Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients.” Open Forum Infect Dis, vol. 11, no. 7, July 2024, p. ofae335. Pubmed, doi:10.1093/ofid/ofae335.
Ni B, Wolfe CR, Arif S, Carugati M, Heldman MR, Messina JA, Miller RA, Saullo JL, Baker AW, Maziarz EK. Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients. Open Forum Infect Dis. 2024 Jul;11(7):ofae335.
Published In
Open Forum Infect Dis
DOI
ISSN
2328-8957
Publication Date
July 2024
Volume
11
Issue
7
Start / End Page
ofae335
Location
United States
Related Subject Headings
- 3207 Medical microbiology
- 3202 Clinical sciences